Britain Courts Anthropic Amid US Defense Department Dispute 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
STAMFORD, Conn., Sept. 02, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016, at 10:30 a.m. ET in New York.
A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
